Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question
GlobalData, the industry analysis specialist, has released its new report, “Xgeva’s Safety and Efficacy Failings Put Future of Amgen Drug in Question”. The report is an essential source of information for the analysis of scope of approval for Xgeva’s extended indication for patients with CRPC who are at high risk of developing bone metastases. However, the unsatisfactory results, combined with significant safety issues have cast doubt on whether Amgen will receive approval for Xgeva’s additional indication.
The report provides information on the key drivers and challenges of the Prostate cancer market. Its scope includes -
Treatment options available for Bone Metastasis
Xgeva Could Become an Expanded Indication for CRPC patients
Final Call on 26th April 2012: $1 billion sales potential of Amgen at stake
Reasons to buy
The report will enhance your decision-making capability.
It will allow you to understand the scope of success of Xgeva that would give a competitive edge to the company and increase its market share in the oncology segment.